Back to search
FDAFDA · Food and drugs·Recall number D-0016-2021

Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534

Published October 14, 2020 · Recall initiated: January 15, 2020

Summary

FDA records drug Class II recall D-0016-2021, published October 14, 2020 and initiated January 15, 2020. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: a) 54 bottles; b) 26 bottles; Lot: Lots: a) 09AU1911 Exp. 02/28/2022; b) 09SE1904 Exp. 03/31/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
FL, GA
Lot
Lots: a) 09AU1911 Exp. 02/28/2022; b) 09SE1904 Exp. 03/31/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 recalled?

Yes. FDA published recall D-0016-2021 on October 14, 2020. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter